A look behind the scenes at some of the logistics involved in keeping CRISPR proliferating throughout the scientific world.
George Church talks about his disappointment with the Human Genome Project, the blistering price/performance improvements in both DNA synthesis and sequencing, and CRISPR’s strength and weaknesses, in addition to the improvements he hopes to see in its successors.
The deal gives Editas Medicine an exclusive ‘first’ to negotiate for licenses to genome-editing inventions that rise from the sponsored research.
Probably not. But there is an increasing demand for people with data and computing skills, and the life sciences sector in California may be losing the battle with Silicon Valley for those people.
Scientists now have easy access to the full power of CRISPR, without any learning curve, thanks to Synthego’s Engineered Cells Portfolio.
The Norwegian Academy of Science and Letters, which is one of the world’s richest science awards in the world, have announced its award will go to three discoverers of the genome-editing tool, CRISPR-Cas9.
U.S. regulators have put a halt on a clinical trial planned to use CRISPR technology on sickle-cell patients due to ‘unspecified questions’, CRISPR Therapeutics said on Wednesday.
Scientists have successfully developed a far easier way to manipulate different genes by using a common research model, baker’s yeast.